These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 16597674)
1. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. Menne J; Park JK; Agrawal R; Lindschau C; Kielstein JT; Kirsch T; Marx A; Muller D; Bahlmann FH; Meier M; Bode-Böger SM; Haller H; Fliser D FASEB J; 2006 May; 20(7):994-6. PubMed ID: 16597674 [TBL] [Abstract][Full Text] [Related]
2. Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. Biala A; Tauriainen E; Siltanen A; Shi J; Merasto S; Louhelainen M; Martonen E; Finckenberg P; Muller DN; Mervaala E Blood Press; 2010 Jun; 19(3):196-205. PubMed ID: 20429690 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512 [TBL] [Abstract][Full Text] [Related]
4. Complement activation in angiotensin II-induced organ damage. Shagdarsuren E; Wellner M; Braesen JH; Park JK; Fiebeler A; Henke N; Dechend R; Gratze P; Luft FC; Muller DN Circ Res; 2005 Sep; 97(7):716-24. PubMed ID: 16109917 [TBL] [Abstract][Full Text] [Related]
5. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Burnier M; Pruijm M; Wuerzner G Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074 [TBL] [Abstract][Full Text] [Related]
9. Role of the fixed-dose combination lercanidipine-enalapril in renal protection. Egan CG; Pontremoli R J Nephrol; 2011; 24(4):428-37. PubMed ID: 21279953 [TBL] [Abstract][Full Text] [Related]